Trehalose-Induced Remodelling of the Human Microbiota Affects
Clostridium difficile
human microbiota
in vitro gut model
microbial competition
trehalose
Journal
Frontiers in cellular and infection microbiology
ISSN: 2235-2988
Titre abrégé: Front Cell Infect Microbiol
Pays: Switzerland
ID NLM: 101585359
Informations de publication
Date de publication:
2021
2021
Historique:
received:
26
02
2021
accepted:
02
06
2021
entrez:
19
7
2021
pubmed:
20
7
2021
medline:
24
7
2021
Statut:
epublish
Résumé
Within the human intestinal tract, dietary, microbial- and host-derived compounds are used as signals by many pathogenic organisms, including
Identifiants
pubmed: 34277467
doi: 10.3389/fcimb.2021.670935
pmc: PMC8284250
doi:
Substances chimiques
Anti-Bacterial Agents
0
Trehalose
B8WCK70T7I
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
670935Informations de copyright
Copyright © 2021 Buckley, Moura, Arai, Spittal, Clark, Nishida, Harris, Bentley, Davis, Wang, Mitra, Higashiyama and Wilcox.
Déclaration de conflit d'intérêts
MW has received honoraria for consultancy work, financial support to attend meetings and research funding from Astellas, AstraZeneca, Abbott, Actelion, Alere, AstraZeneca, Bayer, bioMérieux, Cerexa, Cubist, Da Volterra, Durata, Merck, Nabriva Therapeutics plc, Pfizer, Qiagen, Roche, Seres Therapeutics Inc., Synthetic Biologics, Summit and The Medicines Company. IBM has received support to attend meetings from Techlabs Inc. AB has received research funding from Seres Therapeutics Inc., Motif Biosciences plc., Nabriva Therapeutics plc, Tetraphase Pharmaceuticals, and Hayashibara Co. Ltd. Authors NA, YN and TH were employed by Hayashibara Co. Ltd./NAGASE Group. The authors declare that this study received funding from Hayashibara Co. Ltd. The funder had the following involvement in the study: measuring trehalose and glucose concentrations from each vessel in all of the gut models by HPLC. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Antimicrob Chemother. 2014 Sep;69(9):2426-33
pubmed: 24816211
Cell Rep. 2019 Apr 16;27(3):750-761.e7
pubmed: 30995474
Dis Model Mech. 2015 Jan;8(1):1-16
pubmed: 25561744
Nat Microbiol. 2018 Jun;3(6):662-669
pubmed: 29686297
Front Microbiol. 2017 Jul 17;8:1265
pubmed: 28769880
Antimicrob Agents Chemother. 2001 Aug;45(8):2340-7
pubmed: 11451694
Biochem Biophys Res Commun. 2005 Sep 30;335(3):659-66
pubmed: 16098481
Gut Microbes. 2019;10(2):204-209
pubmed: 30118389
Protein Sci. 2009 Jan;18(1):24-36
pubmed: 19177348
Sci Rep. 2016 May 11;6:25945
pubmed: 27166072
JPEN J Parenter Enteral Nutr. 2018 Sep;42(7):1156-1167
pubmed: 29385239
J Antimicrob Chemother. 2003 Jul;52(1):96-102
pubmed: 12775682
Gastroenterology. 2018 Nov;155(5):1495-1507.e15
pubmed: 30025704
Nature. 2018 Jan 18;553(7688):291-294
pubmed: 29310122
Int J Syst Evol Microbiol. 2008 Aug;58(Pt 8):1896-902
pubmed: 18676476
Antimicrob Agents Chemother. 2019 Jan 29;63(2):
pubmed: 30455242
Antimicrob Agents Chemother. 1991 Jun;35(6):1108-11
pubmed: 1929250
J Clin Invest. 2019 Aug 12;129(9):3792-3806
pubmed: 31403473
PLoS Comput Biol. 2016 Jun 21;12(6):e1004957
pubmed: 27327495
Mol Biol Cell. 1999 Jun;10(6):1859-72
pubmed: 10359602
Biosci Biotechnol Biochem. 1995 Oct;59(10):1829-34
pubmed: 8534970
Clin Infect Dis. 2012 Aug;55 Suppl 2:S93-103
pubmed: 22752871
Appl Environ Microbiol. 2009 Dec;75(23):7537-41
pubmed: 19801464
Cell Host Microbe. 2014 Dec 10;16(6):770-7
pubmed: 25498344
Gut Microbes. 2011 May-Jun;2(3):145-58
pubmed: 21804357
mSystems. 2017 Jul 25;2(4):
pubmed: 28761936
Arch Microbiol. 2000 Oct;174(4):217-24
pubmed: 11081789
Glycobiology. 2003 Apr;13(4):17R-27R
pubmed: 12626396
Microbiome. 2013 Jan 09;1(1):3
pubmed: 24467987
Antimicrob Agents Chemother. 2009 May;53(5):2202-4
pubmed: 19223641
J Bacteriol. 2008 Apr;190(7):2505-12
pubmed: 18245298
Ther Clin Risk Manag. 2015 Apr 13;11:595-603
pubmed: 25926736
J Antimicrob Chemother. 2015 Jan;70(1):182-9
pubmed: 25190720
Antimicrob Agents Chemother. 2009 Feb;53(2):412-20
pubmed: 18710908
Aliment Pharmacol Ther. 2016 Oct;44(7):715-727
pubmed: 27481036
Gut Microbes. 2020 Sep 2;11(5):1475-1482
pubmed: 32329657
Open Forum Infect Dis. 2020 Jan 04;7(1):ofz548
pubmed: 31976356
J Antimicrob Chemother. 2013 Aug;68(8):1842-9
pubmed: 23557928
Clin Infect Dis. 2014 Aug 1;59(3):345-54
pubmed: 24799326
J Antimicrob Chemother. 2005 Jun;55(6):974-82
pubmed: 15860551
J Gen Microbiol. 1990 Dec;136(12):2527-35
pubmed: 2127802
Environ Microbiol. 2018 Apr;20(4):1419-1435
pubmed: 29349925
J Bioenerg Biomembr. 2005 Dec;37(6):411-3
pubmed: 16691474
Nucleic Acids Res. 2017 Jan 4;45(D1):D158-D169
pubmed: 27899622
J Antimicrob Chemother. 2013 Jan;68(1):168-76
pubmed: 22966180
J Antimicrob Chemother. 2014 Mar;69(3):697-705
pubmed: 24128668
Nat Rev Microbiol. 2009 Jul;7(7):526-36
pubmed: 19528959
mBio. 2015 Feb 24;6(2):e02569
pubmed: 25714717
BMC Biol. 2016 Jan 11;14:3
pubmed: 26754945
Comp Med. 2010 Oct;60(5):336-47
pubmed: 21262117
EBioMedicine. 2019 May;43:347-355
pubmed: 31036529
Sci Transl Med. 2018 Oct 24;10(464):
pubmed: 30355801
Nature. 2014 Nov 20;515(7527):423-6
pubmed: 25231861
NPJ Biofilms Microbiomes. 2017 Dec 5;3:35
pubmed: 29214047
J Med Microbiol. 2011 Aug;60(Pt 8):1174-1180
pubmed: 21330415
PeerJ. 2016 Oct 18;4:e2584
pubmed: 27781170
Proc Natl Acad Sci U S A. 2005 Aug 2;102(31):11070-5
pubmed: 16033867
J Antimicrob Chemother. 2015 Sep;70(9):2598-607
pubmed: 26078392
J Bacteriol. 2013 Feb;195(4):844-54
pubmed: 23222730
J Bacteriol. 1964 Jan;87:162-70
pubmed: 14102850
Nat Methods. 2015 Jan;12(1):59-60
pubmed: 25402007
Front Microbiol. 2018 Aug 21;9:1970
pubmed: 30186274
J Antimicrob Chemother. 2012 Apr;67(4):951-4
pubmed: 22279183
J Antimicrob Chemother. 2014 Feb;69(2):451-62
pubmed: 24003182
J Clin Microbiol. 2012 Dec;50(12):4078-82
pubmed: 23052318